The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity
The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: To review emerging data on the relationship between lipoprotein(a) and oxidized phospholipids. RECENT FINDINGS: We have recently proposed that a unique physiological role of lipoprotein(a) may be to bind and transport proinflammatory oxidized phospholipids and that this interaction may mediate a common biological influence on cardiovascular disease. In a large series of clinical studies performed to date, a very strong correlation was found between plasma levels of lipoprotein(a) and the content of oxidized phospholipids on apolipoprotein B-100 particles (OxPL/apoB), measured by monoclonal antibody E06, which binds the phosphocholine head group of oxidized phospholipids but not native phospholipids. The correlation of OxPL/apoB to lipoprotein(a) is very strong in individuals with small apolipoprotein(a) isoforms (r = approximately 0.95) and modest in individuals with large isoforms (r = approximately 0.60). In-vitro studies have demonstrated that the vast majority of oxidized phospholipids detected by E06 are bound to lipoprotein(a) in human plasma. A similarly strong association with oxidized phospholipids was also documented in transgenic mice overexpressing lipoprotein(a), even in mice not fed atherogenic diets or with overt atherosclerosis. SUMMARY: A better understanding of the ability of human lipoprotein(a) to bind oxidized phospholipids may allow clinically important insights into the role of oxidized phospholipids and lipoprotein(a) in human athero…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In vivo, circulating Ox-PLs are mostly carried by the lipoprotein(a) (Lp(a)) fraction,46”
From Calcific aortic stenosis (2016) · cites this paper as [46]
Citations
Cites
Glass, C. K., & Witztum, J. L. (2001) · Cell · doi:10.1016/s0092-8674(01)00238-0 · Cited by 3,051
Self-citationcDNA sequence of human apolipoprotein(a) is homologous to plasminogen
McLean, J. W., Tomlinson, J. E., Kuang, W.-J., Eaton, D. L., Chen, E. Y., Fless, G. M., Scanu, A. M., & Lawn, R. M. (1987) · Nature · doi:10.1038/330132a0 · Cited by 1,886
A NEW SERUM TYPE SYSTEM IN MAN—THE Lp SYSTEM
Berg, K. (1963) · Acta Pathologica Microbiologica Scandinavica · doi:10.1111/j.1699-0463.1963.tb01808.x · Cited by 1,372
Lipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies
Danesh, J., Collins, R., & Peto, R. (2000) · Circulation · doi:10.1161/01.cir.102.10.1082 · Cited by 938
Oxidized Phospholipids, Lp(a) Lipoprotein, and Coronary Artery Disease
Tsimikas, S., Brilakis, E. S., Miller, E. R., McConnell, J. P., Lennon, R. J., Kornman, K. S., Witztum, J. L., & Berger, P. B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043175 · Cited by 784
Self-citationEhara, S., Ueda, M., Naruko, T., Haze, K., Itoh, A., Otsuka, M., Komatsu, R., Matsuo, T., Itabe, H., Takano, T., et al. (2001) · Circulation · doi:10.1161/01.cir.103.15.1955 · Cited by 781
Binder, C. J., Hörkkö, S., Dewan, A., Chang, M.-K., Kieu, E. P., Goodyear, C. S., Shaw, P. X., Palinski, W., Witztum, J. L., & Silverman, G. J. (2003) · Nature Medicine · doi:10.1038/nm876 · Cited by 737
Self-citationNavab, M., Ananthramaiah, G. M., Reddy, S. T., Van Lenten, B. J., Ansell, B. J., Fonarow, G. C., Vahabzadeh, K., Hama, S., Hough, G., Kamranpour, N., et al. (2004) · Journal of Lipid Research · doi:10.1194/jlr.r400001-jlr200 · Cited by 688
Shaw, P. X., Hörkkö, S., Chang, M.-K., Curtiss, L. K., Palinski, W., Silverman, G. J., & Witztum, J. L. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8472 · Cited by 676
Self-citationInnate and acquired immunity in atherogenesis
Binder, C. J., Chang, M.-K., Shaw, P. X., Miller, Y. I., Hartvigsen, K., Dewan, A., & Witztum, J. L. (2002) · Nature Medicine · doi:10.1038/nm1102-1218 · Cited by 642
Self-citation
Cited by
Lindman, B. R., Clavel, M.-A., Mathieu, P., Iung, B., Lancellotti, P., Otto, C. M., & Pibarot, P. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.6 · Cited by 982
Kinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., Umemoto, S., Egusa, G., Ohmura, H., Okamura, T., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2017 · Cited by 813
van der Valk, F. M., Bekkering, S., Kroon, J., Yeang, C., Van den Bossche, J., van Buul, J. D., Ravandi, A., Nederveen, A. J., Verberne, H. J., Scipione, C., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.020838 · Cited by 674
“Results—We show that subjects with elevated Lp(a) (108 [50-195] mg/dL; n=30) have increased arterial inflammation and enhanced PBMCs trafficking to the arterial wall, compared with subjects with normal Lp(a) (7 [2-28] mg/dL; n=30).”
Self-citationGeneration and Biological Activities of Oxidized Phospholipids
Bochkov, V. N., Oskolkova, O. V., Birukov, K. G., Levonen, A.-L., Binder, C. J., & Stöckl, J. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2597 · Cited by 610
Haycock, P. C., Burgess, S., Wade, K. H., Bowden, J., Relton, C., & Davey Smith, G. (2016) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.115.118216 · Cited by 600
Pathological aspects of lipid peroxidation
Negre-Salvayre, A., Auge, N., Ayala, V., Basaga, H., Boada, J., Brenke, R., Chapple, S., Cohen, G., Feher, J., Grune, T., et al. (2010) · Free Radical Research · doi:10.3109/10715762.2010.498478 · Cited by 449
The role of oxidized phospholipids in atherosclerosis
Berliner, J. A., Leitinger, N., & Tsimikas, S. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800074-jlr200 · Cited by 403
Self-citationApolipoprotein(a) Isoforms and the Risk of Vascular Disease
Erqou, S., Thompson, A., Di Angelantonio, E., Saleheen, D., Kaptoge, S., Marcovina, S., & Danesh, J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.10.080 · Cited by 332
Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases
Trpkovic, A., Resanovic, I., Stanimirovic, J., Radak, D., Mousa, S. A., Cenic-Milosevic, D., Jevremovic, D., & Isenovic, E. R. (2015) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2014.992063 · Cited by 321
Okamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 302
Lipoprotein (a): impact by ethnicity and environmental and medical conditions
Enkhmaa, B., Anuurad, E., & Berglund, L. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r051904 · Cited by 260
Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)
Leibundgut, G., Scipione, C., Yin, H., Schneider, M., Boffa, M. B., Green, S., Yang, X., Dennis, E., Witztum, J. L., Koschinsky, M. L., et al. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m040733 · Cited by 243
Self-citationHuman Genetics and the Causal Role of Lipoprotein(a) for Various Diseases
Kronenberg, F. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6648-3 · Cited by 230
“Lp(a) has therefore been proposed to function as a Bsink^ for OxPl [11].”
BackgroundInfluentialNon-genetic influences on lipoprotein(a) concentrations
Enkhmaa, B., & Berglund, L. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.006 · Cited by 193
“Lp(a) is the primary carrier of circulating OxPL and as the OxPL content is hypothesized to mediate its atherogenicity further studies on the impact of diet are warranted [15,16].”
BackgroundTaleb, A., Witztum, J. L., & Tsimikas, S. (2011) · Biomarkers in Medicine · doi:10.2217/bmm.11.60 · Cited by 187
Self-citationLipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment
Lampsas, S., Xenou, M., Oikonomou, E., Pantelidis, P., Lysandrou, A., Sarantos, S., Goliopoulou, A., Kalogeras, K., Tsigkou, V., Kalpis, A., et al. (2023) · Molecules · doi:10.3390/molecules28030969 · Cited by 162
“Thus, certain atheromatic actions of Lp(a) are carried out via OxPLs and include chemotaxis, formation of foam cells, enhancement of inflammation and plaque instability [93,94,97,98].”
Jawi, M., Frohlich, J. J., & Chan, S. (2020) · Journal of Lipids · doi:10.1155/2020/3491764 · Cited by 207
Tsimikas, S., Clopton, P., Brilakis, E. S., Marcovina, S. M., Khera, A., Miller, E. R., de Lemos, J. A., & Witztum, J. L. (2009) · Circulation · doi:10.1161/circulationaha.108.836940 · Cited by 152
Self-citationKotan, V. O., Sarandol, E., Kirhan, E., Ozkaya, G., & Kirli, S. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.03.021 · Cited by 149
Mitochondria as a source and target of lipid peroxidation products in healthy and diseased heart
Anderson, E. J., Katunga, L. A., & Willis, M. S. (2012) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2011.05641.x · Cited by 147
Khandelia, H., & Mouritsen, O. G. (2009) · Biophysical Journal · doi:10.1016/j.bpj.2009.01.007 · Cited by 145
“For example, lipid oxidation products can trigger mitochondrial damage (4) and have been implicated in mediating several diseased states, including cancer (5) and atherosclerosis (6).”
BackgroundCauses and consequences of lipoprotein(a) abnormalities in kidney disease
Kronenberg, F. (2013) · Clinical and Experimental Nephrology · doi:10.1007/s10157-013-0875-8 · Cited by 128
“The close relationship of OxPL/apoB and Lp(a) in predicting cardiovascular events strongly supports the hypothesis that the atherogenicity of Lp(a) may, at least in part, be attributable to its ability to preferentially bind proinflammatory oxidized phospholipids compared with other apoB-containing lipoproteins [12].”
BackgroundPleiotropic effects of oxidized phospholipids
Bochkov, V., Gesslbauer, B., Mauerhofer, C., Philippova, M., Erne, P., & Oskolkova, O. V. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.12.034 · Cited by 124
Merki, E., Graham, M., Taleb, A., Leibundgut, G., Yang, X., Miller, E. R., Fu, W., Mullick, A. E., Lee, R., Willeit, P., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.10.052 · Cited by 124
“Concomitantly with a reduction in apo(a) and Lp(a) levels, OxPLs associated with circulating apo(a)/Lp(a) were reduced in relative proportion to the lowering of apo(a)/Lp(a), consistent with prior observations that Lp(a) is a carrier of proinflammatory OxPLs (6,14,19).”
BackgroundResultSelf-citationScavenger receptor-BI is a receptor for lipoprotein(a)
Yang, X.-P., Amar, M. J., Vaisman, B., Bocharov, A. V., Vishnyakova, T. G., Freeman, L. A., Kurlander, R. J., Patterson, A. P., Becker, L. C., & Remaley, A. T. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m038877 · Cited by 113
Fraley, A. E., Schwartz, G. G., OLSSON, A. G., Kinlay, S., Szarek, M. J., Rifai, N., Libby, P., Ganz, P., Witztum, J. L., & Tsimikas, S. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.041 · Cited by 114
Self-citationDietary Carnosine Prevents Early Atherosclerotic Lesion Formation in Apolipoprotein E–Null Mice
Barski, O. A., Xie, Z., Baba, S. P., Sithu, S. D., Agarwal, A., Cai, J., Bhatnagar, A., & Srivastava, S. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.300572 · Cited by 112
Lipoprotein(a)—The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation
Ugovšek, S., & Šebeštjen, M. (2021) · Biomolecules · doi:10.3390/biom12010026 · Cited by 98
“Lp(a) carries more than 80% OxPLs in its particles, and consequently this increases the inflammatory activity of the arterial wall [21].”
BackgroundInfluentialLipoprotein(a) Induces Human Aortic Valve Interstitial Cell Calcification
Yu, B., Hafiane, A., Thanassoulis, G., Ott, L., Filwood, N., Cerruti, M., Gourgas, O., Shum-Tim, D., Al Kindi, H., de Varennes, B., et al. (2017) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2017.03.015 · Cited by 96
“The latter has long been recognized as a risk factor for cardiac disease, but its exact role in vivo has remained contentious (12).”
Beyond Lipoprotein(a) plasma measurements: Lipoprotein(a) and inflammation
Reyes‐Soffer, G., & Westerterp, M. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105689 · Cited by 100
“This may explain the higher affinity of apo(a) for oxPL when Lp(a) concentrations are high [7,96,98,99].”
BackgroundFaghihnia, N., Tsimikas, S., Miller, E. R., Witztum, J. L., & Krauss, R. M. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m005769 · Cited by 90
Self-citationLipoprotein(a) and inflammation: A dangerous duet leading to endothelial loss of integrity
Pirro, M., Bianconi, V., Paciullo, F., Mannarino, M. R., Bagaglia, F., & Sahebkar, A. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.02.001 · Cited by 95
“Thus, Lp(a)-mediated OxPL scavenging and, in some ircumstances oxPL degradation by Lp(a)-lipoprotein-associated hospholipase A2, may exert anti-inflammatory effects [35,57].”
BackgroundUpdate on the NCEP ATP-III emerging cardiometabolic risk factors
Eckel, R. H., & Cornier, M. (2014) · BMC Medicine · doi:10.1186/1741-7015-12-115 · Cited by 105
“The atherogenicity relates to multiple features of the particle including the inability of the particle to be cleared by the LDL receptor, anti-fibrinolytic properties due to the structural homology to plasminogen and competition with plasminogen for its binding site, and the particle carrying more atherogenic pro-inf…”
BackgroundProtein lipoxidation: Detection strategies and challenges
Aldini, G., Domingues, M. R., Spickett, C. M., Domingues, P., Altomare, A., Sánchez-Gómez, F. J., Oeste, C. L., & Pérez-Sala, D. (2015) · Redox Biology · doi:10.1016/j.redox.2015.05.003 · Cited by 82
“Strong evidence has been accumulating over many years for lipoxidation adducts of aldehydes in atherosclerotic plaques [31–33], while oxidized phosphatidylcholine adducts of ApoB-100, extensively studied in atherosclerosis [34,35], appear to be good biomarkers and predictive of disease [36].”
BackgroundLu, J., Chen, B., Chen, T., Guo, S., Xue, X., Chen, Q., Zhao, M., Xia, L., Zhu, Z., Zheng, L., et al. (2017) · Redox Biology · doi:10.1016/j.redox.2017.04.032 · Cited by 90
“The roles of oxidized PL in atherosclerosis have been a research focus for the past decades and both anti-atherosclerotic and pro-atherosclerotic effects of these oxPLs have been reported [46,47].”
BackgroundLeibundgut, G., Arai, K., Orsoni, A., Yin, H., Scipione, C., Miller, E. R., Koschinsky, M. L., Chapman, M. J., Witztum, J. L., & Tsimikas, S. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.12.033 · Cited by 80
“In a large series of clinical and experimental studies (9), we have established that a key component of the atherogenicity of Lp(a) and its value in predicting new cardiovascular events (3,13) may be its unique property, among lipoproteins, to preferentially bind and transport proinflammatory OxPL.”
BackgroundSelf-citationSerbulea, V., Upchurch, C. M., Ahern, K. W., Bories, G. F. P., Voigt, P. E., DeWeese, D. E., Meher, A. K., Harris, T. E., & Leitinger, N. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.11.002 · Cited by 78
Dzobo, K. E., Cupido, A. J., Mol, B. M., Stiekema, L. C. A., Versloot, M., Winkelmeijer, M., Peter, J., Pennekamp, A.-M., Havik, S. R., Vaz, F. M., et al. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319937 · Cited by 76
Self-citationAcute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia
Arai, K., Orsoni, A., Mallat, Z., Tedgui, A., Witztum, J. L., Bruckert, E., Tselepis, A. D., Chapman, M. J., & Tsimikas, S. (2012) · Journal of Lipid Research · doi:10.1194/jlr.p027235 · Cited by 67
Self-citationNicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice
Chennamsetty, I., Kostner, K. M., Claudel, T., Vinod, M., Frank, S., Weiss, T. S., Trauner, M., & Kostner, G. M. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m029769 · Cited by 66
Genetic Variants in the Apolipoprotein(a) Gene and Coronary Heart Disease
Li, Y., Luke, M. M., Shiffman, D., & Devlin, J. J. (2011) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.111.959601 · Cited by 70
Lipoprotein(a): A Promising Marker for Residual Cardiovascular Risk Assessment
Cai, A., Li, L., Zhang, Y., Mo, Y., Mai, W., & Zhou, Y. (2013) · Disease Markers · doi:10.1155/2013/563717 · Cited by 58
“And the underlying mechanisms can be generally ascribed to the following aspects such as amplifying oxidative stress, inducing endothelial cells necrosis, promoting monocytes, macrophages migration, and foam cells formation, and expanding necrotic lipid core [68].”
BackgroundLipoprotein(a): Genotype–Phenotype Relationship and Impact on Atherogenic Risk
Enkhmaa, B., Anuurad, E., Zhang, W., Tran, T. P., & Berglund, L. (2011) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2011.0026 · Cited by 52
“Of note, the correlation between OxPL and Lp(a) level was stronger in individuals with smaller apo(a) isoforms than in individuals with larger apo(a) isoforms.(51) OxPLs can alter intracellular redox status and activate proinflammatory genes, leading to inflammatory cascades in the vessel wall.”
BackgroundLipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects
Schmitz, G., & Orsó, E. (2015) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-015-0074-0 · Cited by 52
“The levels of oxidized phospholipids are modified by the activity of lipoprotein-associated phospholipase A2 (Lp-PLA2, former platelet activating factor acetylhydrolase, PAFAH), which converts oxidized phospholipids to oxidized fatty acids and lysophosphatidylcholine (lysoPC) [24, 28].”
BackgroundLipids, Lipoproteins, and Cardiovascular Disease: Clinical Pharmacology Now and in the Future
Chait, A., & Eckel, R. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3940 · Cited by 54
Sorensen, C. M., Ding, J., Zhang, Q., Alquier, T., Zhao, R., Mueller, P. W., Smith, R. D., & Metz, T. (2010) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2010.04.075 · Cited by 49
Lipoprotein(a) as a Causal Risk Factor for Cardiovascular Disease
Doherty, S., Hernandez, S., Rikhi, R. R., Mirzai, S., Reyes, C. D. L., McIntosh, S. W., Block, R., & Shapiro, M. D. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00760-1 · Cited by 62
Verweij, S. L., de Ronde, M. W. J., Verbeek, R., Boekholdt, S. M., Planken, R. N., Stroes, E. S. G., & Pinto‐Sietsma, S. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.02.007 · Cited by 44
Arai, K., Luke, M. M., Koschinsky, M. L., Miller, E. R., Pullinger, C. R., Witztum, J. L., Kane, J. P., & Tsimikas, S. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.09.077 · Cited by 44
Self-citationYang, X., Sethi, A. A., Yanek, L. R., Knapper, C., Nordestgaard, B. G., Tybjærg‐Hansen, A., Becker, D. M., Mathias, R. A., Remaley, A. T., & Becker, L. C. (2016) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.116.001402 · Cited by 42
“On the other hand, Lp(a) is generally viewed as proatherogenic.(16,24,46)”
Purushothaman, K., Meerarani, P., Levy, A. P., Lento, P. A., Evrard, S., Kovacic, J. C., Briley-Saebo, K. C., Tsimikas, S., Witztum, J. L., Krishnan, P., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.04.011 · Cited by 44
Self-citationLipidomics of Bioactive Lipids in Acute Coronary Syndromes
Solati, Z., & Ravandi, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051051 · Cited by 42
“The ten-year follow-up of this population showed that risk of cardiovascular events, which was defined as cardiovascular death, MI, stroke, and transient ischemic attack (TIA), were significantly elevated in participants in the highest tertile of OxPLs/apoB than those in the lowest tertile independent of traditional r…”
BackgroundInfluentialQin, T., Ma, T., Huang, K., Lu, S., Zhong, J., & Li, J. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01215-5 · Cited by 44
“Up to 90% of all oxPLs in human lipoproteins are transported by Lp(a), highlighting its role as the primary carrier [34, 62].”
BackgroundSharma, M., Von Zychlinski-Kleffmann, A., Porteous, C. M., Jones, G. T., Williams, M. J. A., & McCormick, S. P. A. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m056150 · Cited by 32
Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?
Tsioulos, G., Kounatidis, D. C., Vallianou, N. G., Poulaki, A., Kotsi, E., Christodoulatos, G. S., Tsilingiris, D., Karampela, Ι., Skourtis, A., & Dalamaga, Μ. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063537 · Cited by 40
“OxPLs, carried by Lp(a), contribute to these actions similarly to LDL molecules [103].”
BackgroundOxidised phospholipids as biomarkers in human disease
Philippova, M., Resink, T. J., Erné, P., & Bochkov, V. (2014) · Swiss Medical Weekly · doi:10.4414/smw.2014.14037 · Cited by 35
Sex hormones and lipoprotein(a) concentration
Gaeta, G. B., Lanero, S., Barra, S., Silvestri, N., Cuomo, V., Materazzi, C., & Vitagliano, G. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.548804 · Cited by 35
“Recently, it has been hypothesized that Lp(a) acts as the main scavenger for oxidized phospholipids [22] and these complexes could accumulate in the vessel wall [1].”
BackgroundKiechl, S. J., & Willeit, J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.12.048 · Cited by 35
Xu, Y., Ashline, D. J., Liu, L., Tassa, C., Shaw, S. Y., Ravid, K., Layne, M. D., Reinhold, V. N., & Robbins, P. W. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m053017 · Cited by 31
Orsó, E., Ahrens, N., Dzenan, Ć., & Schmitz, G. (2009) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(09)71816-1 · Cited by 34
“By using a set of epitope-specific monoclonal antibodies (particularly E06, but also IK17 and MDA2), recognizing oxidized but not native phospholipids, plasma levels of oxidized phospholipids correlated with concentrations of Lp(a) in plasma, apo(a) size polymorphism and cumulative biohazard of CVD [17] (Figure 1).”
BackgroundInfluentialFefer, P., Tsimikas, S., Segev, A., Sparkes, J. D., Otsuma, F., Kolodgie, F. D., Virmani, R., Juliano, J., Charron, T., & Strauss, B. H. (2011) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2011.08.001 · Cited by 30
“However, we have shown that stains and low fat diets tend to increase OxPL/apoB and Lp(a), which may reflect a flux of OxPL from the vessel wall as suggested in animal studies [20,33] or up-regulation of Lp(a), and its OxPL content, by statins.”
BackgroundResultSelf-citationCai, A., Li, L., Zhang, Y., Mo, Y., Li, Z., Mai, W., & Zhou, Y. (2013) · Disease Markers · doi:10.1155/2013/472845 · Cited by 29
“Secondly, it has been identified that, in the normolipidemic individuals, Lp(a) is capable of removing oxidized phospholipids (such as oxLDL-C) from circulation system via its ability to biding these proinflammatory and prothrombosis materials [23].”
BackgroundLipoprotein(a), a Lethal Player in Calcific Aortic Valve Disease
Hu, J., Lei, H. C., Liu, L., & Xu, D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.812368 · Cited by 28
“, 2017), can promote theAV calcification (Tsimikas and Witztum, 2008).”
BackgroundImplication of Lipids in Calcified Aortic Valve Pathogenesis: Why Did Statins Fail?
Nsaibia, M. J., Devendran, A. S., Goubaa, E., Bouitbir, J., Capoulade, R., & Bouchareb, R. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11123331 · Cited by 30
“In vitro studies showed that Ox-LDL and several oxidized phospholipid (Ox-PL) species carried by the Lp(a) fraction promote the calcification of VICs [44].”
BackgroundLooking at Lp(a) and Related Cardiovascular Risk: from Scientific Evidence and Clinical Practice
Stulnig, T. M., Morozzi, C., Reindl‐Schwaighofer, R., & Stefanutti, C. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0803-9 · Cited by 28
Bourgeois, R., Bourgault, J., Després, A.-A., Perrot, N., Guertin, J., Girard, A. S., Mitchell, P. L., Gotti, C., Bourassa, S., Scipione, C. A., et al. (2021) · Metabolites · doi:10.3390/metabo11070459 · Cited by 27
“Lp(a) not only possesses the atherogenic properties of LDL, but it was found to be the preferential carrier of proinflammatory oxidized phospholipids [26] (OxPL).”
BackgroundEdelstein, C., Pfaffinger, D., Yang, M., Hill, J. S., & Scanu, A. M. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.03.009 · Cited by 23
Oxidized phospholipids and lipoprotein(a): An update
Koutsogianni, A. D., Liberopoulos, E. N., Tellis, K., & Tselepis, A. D. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13710 · Cited by 26
Harding, S., Rideout, T. C., & Jones, P. J. H. (2012) · Journal of Dietary Supplements · doi:10.3109/19390211.2012.683136 · Cited by 27
The role of sphingolipids in meibomian gland dysfunction and ocular surface inflammation
Paranjpe, V., Galor, A., Grambergs, R. C., & Mandal, N. A. (2022) · The Ocular Surface · doi:10.1016/j.jtos.2022.07.006 · Cited by 22
Lipoprotein(a) accelerates atherosclerosis in uremic mice
Pedersen, T. X., McCormick, S. P. A., Tsimikas, S., Bro, S., & Nielsen, L. B. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m006742 · Cited by 19
Self-citationHyperlipoproteinemia (a) is associated with breast cancer in a Han Chinese population
Xu, J., Qiu, X., Li, Y., Sun, N., Zhang, Y., & Shu, J. (2020) · Medicine · doi:10.1097/md.0000000000022037 · Cited by 18
“Moreover, LP(a) carries atherosclerosis-causing cholesterol and oxidized phospholipids that recruit inflammatory cells to vessel walls.([12]) Numerous studies have identified LP(a) as”
BackgroundBerglund, L., Kim, K., Zhang, W., Prakash, N., Truax, K., Anuurad, E., & Enkhmaa, B. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.020158 · Cited by 17
Hromadníková, I., Kotlabová, K., Dvořáková, L., & Krofta, L. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8040544 · Cited by 19
Lopez, L. R., Kobayashi, K., Matsunami, Y., & Matsuura, E. (2008) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-008-8096-8 · Cited by 19
“Lp(a), and that the physiological role of Lp (a) is to bind to proinflammatory oxidized phospholipids (oxPL) and mediate clearance of oxPL [ 41 ].”
BackgroundPhilippova, M., Oskolkova, O., Bicker, W., Schoenenberger, A. W., Resink, T. J., Erné, P., & Bochkov, V. N. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.05.027 · Cited by 16
Konerman, M. C., Kulkarni, K. R., Toth, P. P., & Jones, S. R. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.01.004 · Cited by 16
Molecular Model of Plasma PAF Acetylhydrolase-Lipoprotein Association: Insights from the Structure
Srinivasan, P., & Bahnson, B. J. (2010) · Pharmaceuticals · doi:10.3390/ph3030541 · Cited by 15
“Lp(a) is proposed to be the carrier of pro-inflammatory oxidized phospholipids and an elevated Lp(a) level has been shown to be associated with an increased risk of cardiovascular diseases (reviewed in [31,32]).”
BackgroundOxidative stress: Lipid peroxidation products as predictors in disease progression
Halder, S., & Bhattacharyya, M. (2014) · Journal of Experimental and Integrative Medicine · doi:10.5455/jeim.210414.rw.007 · Cited by 18
“However, high levels of OxPLs in Lp(a) are highly pro-atherogenic as they bind the vessel wall, where they exert pro-inflammatory and prothrombotic properties [89].”
BackgroundPotential of lipoproteins as biomarkers in acute myocardial infarction
Khan, H. A., Ekhzaimy, A., Khan, I., & Sakharkar, M. K. (2017) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2017.7403 · Cited by 14
“In addition, Lp(a) transports the more atherogenic proinflammatory-oxidized phospholipids, which attract inflammatory cells to vessel walls and leads to smooth muscle cell proliferation that facilitates plaque build up (35).”
Németh, Á., Daróczy, B., Juhász, L., Fülöp, P., Harangi, M., & Paragh, G. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.849197 · Cited by 16
“Oxidized phospholipids trigger the endocytosis of Lp(a) through the binding to scavenger receptors of macrophages, as well as the migration of vascular smooth muscle cells from the media to the intima, ultimately leading to endothelial dysfunction (Wu et al., 2004; Tsimikas and Witztum, 2008).”
BackgroundMechanism of oxidized phospholipid-related inflammatory response in vascular ageing
Wang, T., Wang, Y., Zhang, X., Xu, W., Jin, K., Pang, Y., Wu, Y., Luo, J., Xu, R., Jiao, L., et al. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101888 · Cited by 12
Lipoprotein apheresis in patients with peripheral artery disease and hyperlipoproteinemia(a)
Poller, W. C., Dreger, H., Morgera, S., Berger, A., Flessenkämper, I., & Enke-Melzer, K. (2015) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2015.02.032 · Cited by 12
Hrovat, K., Likozar, A. R., Zupan, J., & Šebeštjen, M. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9070211 · Cited by 14
“Lp(a) carries more than 80% oxidized phospholipids in its particles, and consequently this increases the inflammatory activity of the arterial wall [38].”
BackgroundMitsuda, T., Uemura, Y., Ishii, H., Tanaka, A., Takemoto, K., Koyasu, M., Ishikawa, S., Shibata, R., Watarai, M., & Murohara, T. (2019) · Coronary Artery Disease · doi:10.1097/mca.0000000000000798 · Cited by 13
Pattarabanjird, T., Nguyen, A. T., McSkimming, C. C., Dinh, H. Q., Marshall, M. A., Ghosheh, Y., Gulati, R., Durant, C., Vallejo, J., Saigusa, R., et al. (2023) · Nature Cardiovascular Research · doi:10.1038/s44161-023-00356-1 · Cited by 14
“Oxidized phospholipids (OxPLs) and their secondary lipid peroxida-tion-derived adducts, known as oxidation-specific epitopes (OSEs), are formed in inflamed tissues, such as atherosclerotic lesions in the artery wall 1–5 , and can mediate further tissue inflammation and damage 4,6–9 .”
BackgroundSelf-citationLiu, F., & Cai, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1583267 · Cited by 10
Lipoprotein (A) in clinical practice.
Jayasinghe, R., Craig, I. H., & Mohan, R. K. A. (2014) · PubMed · Cited by 10
Lipoprotein(a) and Cardiovascular Disease in Heterozygous Familial Hypercholesterolemia
Santos, R. D. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.12.049 · Cited by 10
“increased binding and transport of oxidized phospholipids (9).”
BackgroundKarpouzas, G. A., Papotti, B., Ormseth, S. R., Palumbo, M., Hernández, E., Marchi, C., Zimetti, F., Budoff, M. J., & Ronda, N. (2022) · Rheumatology · doi:10.1093/rheumatology/keac394 · Cited by 9
Targeting Lipoprotein (a): an Evolving Therapeutic Landscape
Man, L. C., Kelly, E. M., & Duffy, D. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0502-0 · Cited by 10
Rodger, E. J., Suetani, R. J., Jones, G. T., Kleffmann, T., Carne, A., Legge, M., & McCormick, S. P. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030383 · Cited by 9
“Interestingly, some clinical trials show a Jshaped curve for coronary artery disease (CAD) risk [18] indicating that at low levels Lp(a) may protect against the development of CAD, but beyond a threshold level, promotes the disease [19].”
BackgroundAltered Functionality of Lipoprotein(a) Impacts on Angiogenesis in Diabetic Retinopathy
Shariatzadeh, M., Nagtzaam, N. M. A., der Zee, L. V. V., van Holten-Neelen, C., Verhoeven, A. J. M., Dehairs, J., Swinnen, J. V., Leijten, F. P. J., ten Berge, J. C., Ciriano, J. P. M., et al. (2023) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.64.5.8 · Cited by 8
“50,51 On the other hand, when present at high concentrations, Lp(a) is atherogenic possibly due to its high affinity to bind to arterial intimal proteoglycans and subsequent increase in intimal concentration of LDL with associated pro-inflammatory OxPLs.”
Shimatsu, Y., Horii, W., Nunoya, T., Iwata, A., Fan, J., & Ozawa, M. (2015) · EXPERIMENTAL ANIMALS · doi:10.1538/expanim.15-0057 · Cited by 23
“Although the physiological functions of Lp(a) remain unclear [28], Lp(a) was recently demonstrated to be selectively enriched in oxidized phospholipids, as detected by murine monoclonal antibody E06, in humans and in Lp(a) transgenic mice expressing a mini-apo(a) construct containing eight kringle IV repeats [1, 21, 2…”
BackgroundJerjes-Sánchez, C. (2015) · Springer eBooks · doi:10.1007/978-3-319-19707-4_1 · Cited by 11
Baldassarre, D., Amato, M., Frigerio, B., Ghezzi, S., Colombo, C., Castelnuovo, S., Ravani, A. L., Sansaro, D., Tremoli, E., Sirtori, C. R., et al. (2014) · Nutrafoods · doi:10.1007/s13749-014-0047-9 · Cited by 9
“Peroxidation may lead to an enhanced production of oxidised lipoproteins [6], complex oxidised phospholipids [7] and F2 isoprostanes (peroxidative products of arachidonic acid) [8, 9] in addition to protein and DNA damage [10].”
BackgroundLipoprotein(a) and Its Role in Peripheral Arterial Disease: A Narrative Review
Mwipatayi, B. P., Dodd, J. E., Bazlee, A. H. A., Stratford, G., Lee, B., Mori, T. A., Watts, G. F., Armari, E., Wong, J., & Schlaich, M. P. (2025) · Vascular Health and Risk Management · doi:10.2147/vhrm.s555127 · Cited by 10
Antibody E06 and the Role of Oxidized Phospholipids in Atherogenesis and Inflammation
Witztum, J. L., Que, X., Tang, W., & Tsimikas, S. (2026) · Circulation Research · doi:10.1161/circresaha.126.327359 · Cited by 7
Self-citationCritical review of non-statin treatments for dyslipoproteinemia
Pang, J., Chan, D. C., & Watts, G. F. (2014) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.888312 · Cited by 7
Krzesińska, A., Marlęga-Linert, J., Chyła-Danił, G., Marcinkowska, M., Rogowska, P., Stumska, K., Fijałkowski, M., Gruchała, M., Jankowski, M., Mickiewicz, A., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413597 · Cited by 5
“The proatherogenic mechanism of Lp(a) action is multidirectional and probably also associated with its importance in binding and transporting proinflammatory oxidized phospholipids (oxPL) [11].”
Metadata
- Authors
- Tsimikas, S., & Witztum, J. L.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Tsimikas, Sotirios
- Venue
- Current Opinion in Lipidology
- Published
- 2008-08
- Volume
- 19
- Issue
- 4
- Pages
- 369-377
- ISSN
- 0957-9672 (ISSN-L)
- OpenAlex
- W1998280774
- Cited by
- 138
- References
- 53
- Citations by year
- 2026: 8 · 2025: 7 · 2024: 8 · 2023: 7 · 2022: 8 · 2021: 7 · 2020: 2 · 2019: 5 · 2018: 2 · 2017: 7 · 2016: 11 · 2015: 12 · 2014: 9 · 2013: 7 · 2012: 10
- FWCI
- 1.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Lipidology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- lipoprotein(a), oxidized phospholipids, atherogenicity, apolipoprotein B-100, apolipoprotein(a) isoforms, atherosclerosis, cardiovascular disease, transgenic mice
- MeSH terms
- Animals, Apolipoproteins B, Humans, Oxidation-Reduction, Phospholipids, Risk, Lipoprotein(a), Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.